Trends in Pharmacological Sciences
Nibbling at CRF receptor control of feeding and gastrocolonic motility
Section snippets
Selective CRF2 receptor ligands
The discovery of endogenous selective CRF2 receptor agonists – the type 2 urocortins (Ucn 2 [9] and Ucn 3 [10]) – opened a new chapter in our understanding of the functional significance of CRF systems in the brain and gut. Because the separate pro-hormones that contain the type 2 urocortins were identified using molecular cloning and database trawling strategies, the existence and structure of the mature peptides remain predicted, rather than known. Evidence 3, 4 favours the 38 amino acid
Satiation-like effects of brain and gut CRF2 receptor activation
In vivo studies with CRF2 receptor ligands suggest an anorectic role for gut CRF2 receptors. The anorectic effects of peripheral Ucn 1, which has been shown to suppress fasting-induced ingestion more potently than does CRF, CCK-8 or leptin [21], were attenuated by intraperitoneal (i.p.) injection of ASVG-30 [21] but not by selective CRF1 receptor antagonists 21, 22. Similarly, i.p. injection of stresscopin and stresscopin-related peptide (CRF2 receptor-selective analogues of Ucn 3 and Ucn 2,
CRF1 versus CRF2 receptor-mediated anorexia
Activation of CRF1 receptors in the brain can suppress feeding independently of CRF2 receptor-mediated mechanisms. For example, selective CRF1 receptor antagonists reverse at least some forms of stress-induced anorexia [26]. CRF1 and CRF2 receptor-mediated anorexia appear to exhibit different time-courses. In rats, i.c.v. administration of CRF1 receptor agonists elicited abbreviated, short-onset anorexia, CRF2 receptor agonists provoked delayed-onset anorexia, and nonselective CRF receptor
Stress inhibits gastric motility via brain and gut CRF2 receptor activation
In addition to their anorectic effects, stressors inhibit gastric motor function in a manner that is reversible by central pretreatment with nonselective CRF receptor antagonists 27, 28. Central administration of nonselective CRF receptor agonists has also been shown to delay gastric meal emptying [27]. Through vagal mechanisms, central infusion of nonselective CRF receptor agonists has been shown to reduce antral gastric motility, inhibit high-amplitude gastric contractions, and shift duodenal
Stress stimulates colonic motility via CRF1 receptor activation
In contrast to the inhibition of gastric motility, diverse stressors stimulate colonic motor function, manifesting as increased colonic motility, decreased colonic transit time, stimulated fecal output and watery diarrhoea. Central and peripheral administration of nonselective or preferential CRF1 27, 28, 35, but not CRF2 28, 32, receptor agonists, produces stress-like effects on colonic activity. Conversely, selective CRF1, but not CRF2, receptor antagonists attenuate stress- 27, 35, 36, 37 or
Physiological relevance of brain and gut CRF2 receptors
Discovered for their hypophysiotropic role in the endocrine stress response, CRF and the CRF1 receptor are commonly viewed as mediators that integrate the organism response to stress, a perspective consistent with the reviewed role of CRF1 receptors in stress-induced stimulation of colonic motility. By association, stress-related properties are often expected for the urocortins and the CRF2 receptor. Figure 3 outlines a proposed framework for understanding the adaptive roles of CRF-related
Acknowledgments
E.P.Z. and G.F.K. were supported by NIH DK26741. Y.T.'s work was supported by NIH DK33061, NIH DK57238 and a VA merit award. We gratefully recognize the editorial assistance of Mike Arends. This is publication number 15648-NP from The Scripps Research Institute.
References (60)
The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance
Eur. J. Pharmacol.
(2002)- et al.
The CRF peptide family and their receptors: yet more partners discovered
Trends Pharmacol. Sci.
(2002) - et al.
Distribution of urocortin in the rat's gastrointestinal tract and its colocalization with tyrosine hydroxylase
Peptides
(2002) Design, synthesis and pharmacological characterization of new highly selective CRF2 antagonists: development of 123I-K31440 as a potential SPECT ligand
Peptides
(2002)Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity
Peptides
(2002)Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide
Brain Res.
(2002)Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats
Brain Res.
(1999)The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist
Bioorg. Med. Chem.
(2000)Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats
Brain Res.
(2000)Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats
Gastroenterology
(2000)